Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard Sells 24,000 Shares

Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 24,000 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $26.00, for a total transaction of $624,000.00. Following the sale, the vice president now directly owns 24,000 shares in the company, valued at $624,000. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Heron Therapeutics stock opened at $26.61 on Wednesday. Heron Therapeutics Inc has a one year low of $15.68 and a one year high of $29.49. The business’s fifty day moving average is $21.72 and its 200 day moving average is $19.08. The stock has a market capitalization of $2.30 billion, a PE ratio of -10.91 and a beta of 1.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.76 and a quick ratio of 3.51.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.15. The business had revenue of $42.62 million during the quarter, compared to analyst estimates of $34.02 million. Heron Therapeutics had a negative return on equity of 60.76% and a negative net margin of 140.55%. Heron Therapeutics’s revenue was up 115.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.49) EPS. As a group, sell-side analysts expect that Heron Therapeutics Inc will post -2.44 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Meadow Creek Investment Management LLC purchased a new position in shares of Heron Therapeutics during the second quarter valued at approximately $27,000. Quantum Capital Management bought a new position in Heron Therapeutics during the third quarter valued at approximately $53,000. US Bancorp DE lifted its position in Heron Therapeutics by 75.6% during the second quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 1,769 shares during the period. Tower Research Capital LLC TRC bought a new position in Heron Therapeutics during the third quarter valued at approximately $100,000. Finally, Tiverton Asset Management LLC purchased a new stake in Heron Therapeutics in the second quarter worth approximately $101,000.

HRTX has been the subject of several recent analyst reports. JMP Securities decreased their target price on shares of Heron Therapeutics from $38.00 to $32.00 and set a “market outperform” rating for the company in a report on Thursday, October 3rd. Northland Securities reiterated a “buy” rating and set a $47.00 price target on shares of Heron Therapeutics in a report on Wednesday, November 13th. BidaskClub raised shares of Heron Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 26th. Cowen reissued a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a research report on Tuesday, October 1st. Finally, Evercore ISI restated a “buy” rating and issued a $75.00 price objective on shares of Heron Therapeutics in a report on Tuesday, August 13th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $46.13.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Initial Coin Offering (ICO)

Insider Buying and Selling by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit